New Heart Disease Balloon Trial to Preview at TCT 2026
The Virtue Trial will compare a new balloon-based drug delivery system to existing treatments in 740 patients.
Updated on Oct. 29, 2026 in Heart Disease
Live Poll
Do you trust that newer medical technologies consistently provide better long-term health outcomes for patients?
At the upcoming TCT 2026 symposium in San Diego on November 1, researchers will detail the design of the Virtue Trial, a study investigating a new drug-delivery balloon. This trial aims to enroll 740 patients to evaluate the Virtue Sirolimus AngioInfusion Balloon against the AGENT paclitaxel-coated balloon.
Why it matters
This trial seeks to determine if a novel liquid drug delivery system can effectively inhibit inflammation and vessel wall proliferation in patients with heart disease. San Diego clinicians and patients may gain insights into whether this non-coated delivery method offers a comparable treatment alternative for lesion management.
The Virtue Trial is a randomized, single-blind, non-inferiority study designed to enroll 740 patients, building on earlier findings from the 50-patient SABRE study which recorded a 14.3% three-year target lesion failure rate. The ultimate comparative efficacy of the device remains under investigation.
The players
Orchestra BioMed
A biomedical company developing the Virtue Sirolimus AngioInfusion Balloon for cardiovascular disease treatment.
Medtronic
A global medical device leader that maintains a strategic collaboration with Orchestra BioMed regarding AVIM Therapy.
Allen Jeremias
A cardiologist scheduled to present the design and clinical mechanism of the Virtue Trial.
The details
The Virtue Sirolimus AngioInfusion Balloon functions as a non-coated delivery system that infuses SirolimusEFR directly into the vessel wall via a microporous balloon. By delivering this medication locally, the technology aims to modulate inflammation and inhibit cell proliferation that can lead to vessel narrowing. The trial design will directly test this mechanism against existing paclitaxel-coated balloon technologies.
Timeline
October 31, 2026: TCT 2026 symposium begins at the San Diego Convention Center.
November 1, 2026: Virtue SAB clinical trial design presentation occurs.
November 3, 2026: TCT 2026 symposium concludes.
Health Landscape
This development represents a progression in interventional cardiology toward specialized, localized drug-delivery systems for managing vessel wall health. It reflects the broader trend of testing non-inferiority in drug-coated device alternatives to standard treatment paradigms.
Patients currently discussing treatment options for lesion management may want to monitor these findings as they represent a potential future addition to standard care. Any questions regarding whether new clinical trials are appropriate for your specific condition should be discussed with your physician.
The takeaway
The upcoming trial results will help clarify how drug-infused balloons compare to current standards for heart health. Readers should keep track of long-term data when assessing the progress of new medical devices that treat vascular inflammation.
Further reading
For more information on new treatments for cardiac conditions, visit the Heart Disease section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust that newer medical technologies consistently provide better long-term health outcomes for patients?
